Skip to content


Critical Care

Volume 18 Supplement 2

Sepsis 2014

Open Access

More effective use of polymyxin-B hemoperfusion for nonoperation cases

  • M Yahata1,
  • Y Sakamoto1,
  • S Inoue1,
  • T Iwamura1,
  • R Fujita1,
  • H Koami1,
  • T Miike1,
  • H Imahase1,
  • S Narumi1,
  • A Goto1 and
  • M Ohta1
Critical Care201418(Suppl 2):P32

Published: 3 December 2014


Arterial PressureEmergency MedicineMean Arterial PressureHemodynamic EffectHemodynamic State


Direct hemoperfusion with polymyxin-B has been reported to improve hemodynamics in postsurgical patients. In 2012, the Japanese Guidelines for the Management of Sepsis were published and mention the efficacy of polymyxin-B direct hemoperfusion. But how to use and the target patients are varied by facilities. We investigated the effective use of polymyxin-B direct hemoperfusion in nonsurgical patients.


We analyzed retrospectively all septic shock patients who were treated with polymyxin-B hemoperfusion between January 2008 and December 2012.We checked their mean arterial pressure (MAP), and vasopressor requirement every 30 minutes until stopping treatment.


There were 32 patients under treatment and 11 patients did not need surgical treatment. Even in the nonsurgical group, hemodynamic states and vasopressor requirement was improved after polymyxin-B hemoperfusion started. And the effects were continued over 120 minutes. A second plolymyxin-B hemoperfusion treatment underwent in nine patients. In second treatment, MAP increased in the nonsurgical group greater than in the postsurgical group.


Polymyxyn-B direct hemoperfusion improves hemodynamic status even in nonsurgical patients. A second polymyxin-B direct hemoperfusion is effective especially in nonsurgical septic shock patients. And if its hemodynamic effect was significantly, long-time treatment should be considered.

Authors’ Affiliations

Emergency and Critical Care Medicine, Saga University, Saga, Japan


© Yahata et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.